Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study*

References

• Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med. 2020;383(4):309–320.
   PubMed Web of Science ®Google Scholar
• WHO Expert Consultation on Rabies: third report. [Internet]. World Health Organization. 2018. Available from: https://apps.who.int/iris/bitstream/handle/10665/272364/9789241210218-eng.pdf.
   Google Scholar
• Kuhar DT, Henderson DK, Struble KA, et al. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis [Pamphlet (or booklet)]. 25/2013 Update. 2018.
   Google Scholar
• Redeker AG, Mosley JW, Gocke DJ, et al. Hepatitis B immune globulin as a prophylactic measure for spouses exposed to acute type B hepatitis. N Engl J Med. 1975;293(21):1055–1059.
   PubMed Web of Science ®Google Scholar
• Brunell PA, Ross A, Miller LH, et al. Prevention of varicella by zoster immune globulin. N Engl J Med. 1969;280(22):1191–1194.
   PubMed Web of Science ®Google Scholar
• Slifka MK, Amanna IJ, et al. Passive immunization. In: Orenstein W, Offit PA, Edwards KM, editors. Plotkin’s vaccines. Philadelphia, PA, US: Elsevier Health Sciences; 2018. p. 84–95.
   Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727–733.
   PubMed Web of Science ®Google Scholar
• Walker PGT, Whittaker C, Watson OJ, et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science. 2020;369(6502):413–422.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Coronavirus (COVID-19) Dashboard 2022. Available from: https://covid19.who.int/
   Google Scholar
• Strohl WR, Ku Z, An Z, et al. Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants. BioDrugs. 2022;36(3):231–323.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Coronavirus (COVID-19) Drugs: U.S. Food and Drug Administration; 2023 [updated March 10; cited 2023 March 15]. Available from: https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs
   Google Scholar
• U.S. Food and Drug Administration. Emergency use authorizations for drugs and Non-vaccine biological products: U.S. Food and Drug Administration; 2023 [updated March 10; cited 2023 March 15]. Available from: https://www.fda.gov/drugs/emergency-preparedness-drugs/emergency-use-authorizations-drugs-and-non-vaccine-biological-products
   Google Scholar
• Cao Y, Jian F, Zhang Z, et al. Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cell Rep. 2022 Dec;1:111845.
   Google Scholar
• Cao Y, Jian F, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent omicron RBD evolution. Nature. 2023 Feb;614(7948):521–529.
   PubMed Web of Science ®Google Scholar
• Si S, Jin C, Li J, et al. Safety and effectiveness of SA58 nasal spray against COVID-19 infection in medical personnel: an open-label, blank-controlled study – hohhot city, Inner Mongolia autonomous region, China, 2022. China CDC Weekly. 2023;5(10):218–222.
   PubMedGoogle Scholar
• The State Council PRC. ‘New Tens’ for the control and prevention of COVID-19. 2022 Dec 7. The State Council, P.R. China, 2022. Available from: http://www.nhc.gov.cn/xcs/gzzcwj/202212/8278e7a7aee34e5bb378f0e0fc94e0f0.shtml.
   Google Scholar
• National Health commission of the people’s republic of China. Protocol for prevention and control of COVID-19. Beijing: National Health Commission of the People’s Republic of China; 2022; Available from: http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88.shtml.
   Google Scholar
• NIH National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 5.0. 2017. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_5.0.
   Google Scholar
• Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657–663.
   PubMed Web of Science ®Google Scholar
• Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–582.
   PubMed Web of Science ®Google Scholar
• Xin H, Wang Z, Feng S, et al. Transmission dynamics of SARS-CoV-2 omicron variant infections in Hangzhou, Zhejiang, China, January-February 2022. Int J Inf Dis. 2022;126:132–135.
   PubMed Web of Science ®Google Scholar